Treats benign prostatic hyperplasia (BPH). Sold as Cardura, Cardura Xl. Every FDA application for this active ingredient: 2 branded and 19 generic.
As of Nov 16, 2026, FDA lists 21 applications for Doxazosin Mesylate (sold as Cardura, Cardura Xl), first approved Nov 2, 1990, with 0 new uses approved and 0 published complete response letters.
| Doxazosin Mesylate | Part D | $34.9M | -2% | 525,451 |
| Cardura | Part D | $332K | -13% | 170 |
| Cardura XL | Part D | $142K | -83% | 264 |
| Early Mineralocorticoid Receptor Antagonist Therapy for Low-Renin Essential HypertensionHypertension (HTN), Low-Renin Essential Hypertension · China National Center for Cardiovascular Diseases | Phase 4 | Not yet recruiting | Nov 12, 2026 |
| Alpha-1 Blockade for Alcohol Use Disorder (AUD)Alcohol Use Disorder (AUD) · Brown University | Phase 2 | Active, not recruiting | Oct 23, 2019 |
| Nov 2, 1990 | CarduraNDA 19668 · New molecular entity | Viatris | 23 | Marketed |
| Oct 18, 2000 | Doxazosin MesylateANDA 75426 | Watson Labs Inc | 1 | Discontinued |
| Oct 18, 2000 | Doxazosin MesylateANDA 75432 | Ani Pharms | 2 | Discontinued |
| Oct 18, 2000 | Doxazosin MesylateANDA 75453 | Ivax Sub Teva Pharms | 8 | Discontinued |
| Oct 18, 2000 | Doxazosin MesylateANDA 75466 | Genpharm | 7 | Discontinued |
| Oct 18, 2000 | Doxazosin MesylateANDA 75536 | Teva | 10 | Marketed |
| Oct 18, 2000 | Doxazosin MesylateANDA 75574 | Actavis Elizabeth | 6 | Discontinued |
| Oct 18, 2000 | Doxazosin MesylateANDA 75580 | Apotex | 12 | Marketed |
| Oct 18, 2000 | Doxazosin MesylateANDA 75609 | Nesher Pharms | 1 | Discontinued |
| Oct 18, 2000 | Doxazosin MesylateANDA 75646 | Chartwell Rx | 2 | Discontinued |
| Oct 19, 2000 | Doxazosin MesylateANDA 75509 | Aurobindo Pharma USA | 8 | Marketed |
| Jan 12, 2001 | Doxazosin MesylateANDA 75353 | Teva | 1 | Discontinued |
| Jun 8, 2001 | Doxazosin MesylateANDA 75750 | Pliva | 1 | Discontinued |
| Jun 10, 2004 | Doxazosin MesylateANDA 76161 | Strides Pharma Intl | 3 | Discontinued |
| Feb 22, 2005 | Cardura XlNDA 21269 · New dosage form | Viatris | 8 | Marketed |
| Jun 11, 2014 | Doxazosin MesylateANDA 202824 | Accord Hlthcare | 2 | Marketed |
| Jul 7, 2017 | Doxazosin MesylateANDA 208719 | Zydus Pharms | 0 | Marketed |
| Feb 13, 2018 | Doxazosin MesylateANDA 205210 | Heritage Pharma | 1 | Marketed |
| Apr 17, 2018 | Doxazosin MesylateANDA 209013 | Somerset Theraps LLC | 1 | Marketed |
| Mar 15, 2022 | Doxazosin MesylateANDA 212727 | Rising | 0 | Marketed |
| Jan 10, 2024 | Doxazosin MesylateANDA 212329 | Unichem | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA